Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | GFER | P55789 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.52 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.52 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31329340 | 0.87 | RAB9A (1.00) | RAB9ASMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL3593419 | 0.87 | RAB9A (1.00) | RAB9ASMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL27915820 | 0.85 | RAB9A (0.77) | RAB9ASMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL31329353 | 0.85 | RAB9A (0.77) | RAB9ASMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL31329346 | 0.85 | RAB9A (0.77) | RAB9ASMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL15416993 | 0.85 | RAB9A (0.82) | RAB9ASMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL31329347 | 0.85 | RAB9A (0.77) | RAB9ASMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL27915818 | 0.85 | RAB9A (0.77) | RAB9ASMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL27915817 | 0.85 | RAB9A (0.77) | RAB9ASMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL2028202 | 0.84 | RAB9A (0.71) | RAB9ASMN1; SMN2TP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745443-B2 | Inhibitors of the GPIb-vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20070173489-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-26 | — | — | US | disclosed |
| US-7235558-B2 | Inhibitors of the GPIb—vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| EP-1509516-B1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-01-31 | — | — | EP | disclosed |
| EP-1509516-A1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | Aventis Pharma Deutschland GmbH (DE) | 2005-03-02 | — | — | EP | disclosed |
| US-20040067980-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-08 | — | — | US | disclosed |
| WO-2003104221-A1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-18 | — | — | WO | disclosed |
| EP-1369420-A1 | Inhibitors of the GPib - vWF interaction | Aventis Pharma Deutschland GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173489-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | F13B, F11, F12 | RAB9A 481/4885SMN1; SMN2 4354/4885TP53 3596/4885 |
| US-20040067980-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | F13B, F11, F12 | RAB9A 647/4885SMN1; SMN2 4358/4885TP53 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.